TY - JOUR
T1 - Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab
T2 - Patient-reported outcomes from the APOLLO trial
AU - Terpos, Evangelos
AU - Dimopoulos, Meletios A.
AU - Boccadoro, Mario
AU - Delimpasi, Sosana
AU - Beksac, Meral
AU - Katodritou, Eirini
AU - Moreau, Philippe
AU - Pompa, Alessandra
AU - Symeonidis, Argiris
AU - Bila, Jelena
AU - Oriol, Albert
AU - Mateos, Maria Victoria
AU - Einsele, Hermann
AU - Orfanidis, Ioannis
AU - Gries, Katharine S.
AU - Fastenau, John
AU - Liu, Kevin
AU - He, Jianming
AU - Kampfenkel, Tobias
AU - Qiu, Yanping
AU - Amin, Himal
AU - Carson, Robin
AU - Sonneveld, Pieter
N1 - Funding Information: The APOLLO study was sponsored by the European Myeloma Network (EMN) in collaboration with Janssen Research & Development, LLC. Medical writing and editorial support were provided by Justine Lempart, PhD, and Linda V. Wychowski, PhD, of Eloquent Scientific Solutions and were funded by Janssen Global Services, LLC.
Publisher Copyright: © 2022 Wiley Periodicals LLC.
PY - 2022/4
Y1 - 2022/4
N2 - In the phase 3 APOLLO trial, daratumumab in combination with pomalidomide and dexamethasone (D-Pd) significantly reduced the rate of disease progression or death by 37% relative to Pd alone in patients with relapsed/refractory multiple myeloma (RRMM) who had received ≥1 prior line of therapy including lenalidomide and a proteasome inhibitor. Here, we present patient-reported outcomes (PROs) from APOLLO. Median treatment duration was 11.5 months with D-Pd and 6.6 months with Pd. PRO compliance rates were high and similar in both groups. No changes from baseline were observed for EORTC QLQ-C30 global health status scores in either group, while physical and emotional functioning, disease symptoms, and adverse effects of treatment remained at baseline levels with D-Pd but worsened with Pd. Reductions (p < 0.05) in pain and fatigue were seen at several time points with D-Pd versus Pd. Overall, these results suggest patients' health-related quality of life remained stable when daratumumab was added to Pd, with several results favoring D-Pd versus Pd. These findings complement the significant clinical improvements observed with D-Pd and support its use in patients with RRMM.
AB - In the phase 3 APOLLO trial, daratumumab in combination with pomalidomide and dexamethasone (D-Pd) significantly reduced the rate of disease progression or death by 37% relative to Pd alone in patients with relapsed/refractory multiple myeloma (RRMM) who had received ≥1 prior line of therapy including lenalidomide and a proteasome inhibitor. Here, we present patient-reported outcomes (PROs) from APOLLO. Median treatment duration was 11.5 months with D-Pd and 6.6 months with Pd. PRO compliance rates were high and similar in both groups. No changes from baseline were observed for EORTC QLQ-C30 global health status scores in either group, while physical and emotional functioning, disease symptoms, and adverse effects of treatment remained at baseline levels with D-Pd but worsened with Pd. Reductions (p < 0.05) in pain and fatigue were seen at several time points with D-Pd versus Pd. Overall, these results suggest patients' health-related quality of life remained stable when daratumumab was added to Pd, with several results favoring D-Pd versus Pd. These findings complement the significant clinical improvements observed with D-Pd and support its use in patients with RRMM.
UR - http://www.scopus.com/inward/record.url?scp=85124477259&partnerID=8YFLogxK
U2 - 10.1002/ajh.26480
DO - 10.1002/ajh.26480
M3 - Article
C2 - 35089607
AN - SCOPUS:85124477259
SN - 0361-8609
VL - 97
SP - 481
EP - 490
JO - American Journal of Hematology
JF - American Journal of Hematology
IS - 4
ER -